Anticancer agent reduces complications after stem-cell transplant

Share this article:

Vorinostat, a drug already approved by the FDA for the treatment of cutaneous T-cell lymphoma, has been found to reduce the risk of graft-versus-host disease (GVHD) in persons undergoing allogeneic hematopoietic stem-cell transplantation. In GVHD, donor cells attack the patient's own cells.

“[GVHD] is the most serious complication from transplant that limits our ability to offer it more broadly,” explained lead study author Sung W. Choi, MD, of the University of Michigan (UM) Comprehensive Cancer Center in Ann Arbor, in a statement from the UM Health System. “This study has us cautiously excited that there may be a potential new way to prevent this condition.”

UM researchers found that vorinostat, a histone deacetylase inhibitor, also has anti-inflammatory properties, which could be useful in combating GVHD. After conducting studies in mice, Choi's team enrolled 45 adults (median age 58 years) in a phase 1/2 trial that combined vorinostat with a standard GVHD prophylaxis regimen of tacrolimus and mycophenolate mofetil. Participants were undergoing a reduced-intensity bone-marrow transplant with cells donated from a relative.

At day 100, grade 2-4 acute GVHD was significantly lower among the 45 patients given vorinostat than among control patients receiving standard treatment (22% vs 42%). Severe grade 3-4 acute GVHD at day 100 was also reduced among vorinostat users (4% for vorinostat recipients vs 19% for controls), as was transplant-related mortality at 1 year (13% for vorinostat recipients vs 19% for controls).

“The incidence of [acute] GVHD was globally diminished in all target organs, and all but one patient responded rapidly to standard steroid therapy,” wrote the investigators in an abstract presented at the American Society of Hematology annual meeting held in Atlanta, Georgia, December 8-11, 2012.

The incidence of relapse was similar between the study group and the controls (17% vs 20%, respectively), and no difference was seen in the rate of infectious complications.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

What is this?

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Support team aids decision-making by caregivers of terminal cancer patients

Researchers devised an intervention that quickly integrates a cancer support team to guide caregivers and their patients through difficult end-of-life treatment and decisions.

Protein inhibition opens door for pancreatic cancer treatment

The protein galectin-1 has been identified as a possible therapeutic target for pancreatic cancer; new research has demonstrated that inhibiting this protein in mice with pancreatic cancer increased survival by 20%.

Noninvasive advanced image analysis may improve care for lung cancer patients

Lung cancer patients could receive more precise treatment, and their progress could be better tracked by using a new high-tech method of non-invasive medical imaging analysis, according to a new study.